Skip to content

CNAP Monitor 500I, 500AT

by Cnsystem Medizintechnik AG

510(k) K082599

Active United States

510(k)

Valid until

No expiry

510(k) clearance is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

Trust

Unverified

Registry data, not yet checked by deviCERTS. Source FDA 510(k), synced 22 Oct 2026. What this means

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK082599 Date17 Oct 2008ClearedStatusActive

Recalls

0 recalls · FDA

No FDA recalls found in the data synced 22 Oct 2026.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Specification

510(k)

Full name
Non-Invasive Continuous Blood Pressure Monitoring System Cnap Monitor 500I, 500AT
510(k) Number
FDA Product Code
DXN
Device Class
Class II
Regulation
21 CFR Part 870.1130
Advisory Committee
Cardiovascular
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The CNAP Monitor 500I, 500AT is a non-invasive continuous blood pressure monitoring system designed for real-time assessment of blood pressure waveforms and hemodynamic parameters. It provides beat-to-beat systolic, diastolic, and mean arterial pressure measurements, as well as pulse rate, without requiring invasive procedures.

This device is intended for use in hospital settings, offering continuous monitoring for perioperative fluid management in low- and moderate-risk surgeries. Supplied as a reusable system, it adheres to FDA 510(k) clearance under the traditional review pathway (K082599, SESE) and is manufactured by Cnsystem Medizintechnik AG in Graz, Austria. No specific sterility or MRI safety information is provided in the available data.

Questions

AI-generated answers, 19 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • Is the CNAP Monitor 500I/500AT system designed for use outside of the operating room, or is it specifically for perioperative fluid management only?

    The CNAP Monitor 500I, 500AT is explicitly intended for hospital settings and perioperative fluid management in low- and moderate-risk surgeries. While its primary use is during surgery, the continuous blood pressure monitoring capabilities could theoretically support critical care or recovery monitoring—though this is not explicitly stated in the device description. Always confirm intended use with your facility’s clinical guidelines.

  • How is the CNAP Monitor 500I/500AT system supplied, and can it be reused across multiple patients?

    The system is supplied as a reusable device, meaning it is not single-use. However, reuse requires adherence to your facility’s infection control protocols, as no sterility information is provided in the available data. The manufacturer, Cnsystem Medizintechnik AG, is responsible for maintenance and cleaning instructions, which should be followed strictly to ensure accurate and safe operation.

  • What types of blood pressure measurements does the CNAP Monitor 500I/500AT provide, and how does it differ from traditional cuff-based monitors?

    Unlike traditional intermittent cuff-based monitors, the CNAP Monitor 500I/500AT offers continuous, beat-to-beat measurements of systolic, diastolic, and mean arterial pressure, along with pulse rate. This provides real-time hemodynamic assessment without invasive procedures, making it useful for dynamic perioperative monitoring where fluctuations in blood pressure need immediate attention.

  • What regulatory pathway was followed for FDA clearance of the CNAP Monitor 500I/500AT, and which advisory committee was involved?

    The device received FDA clearance under the traditional review pathway (510(k)) with a Substantially Equivalent (SESE) determination. The review was conducted by the Cardiovascular (CV) Advisory Committee, and the clearance was granted on October 17, 2008, under the product code DXN. This pathway ensures the device meets FDA standards for non-invasive blood pressure monitoring.